Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1365-2044.2011.06641.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Factors Associated With Decision to Use and Dosing of Sugammadex in Children: A Retrospective Cross-Sectional Observational Study.
Anesth Analg
January 2025
From the Department of Anesthesiology, University of Michigan, Ann Arbor, Michigan.
Background: Sugammadex was initially approved for reversal of neuromuscular blockade in adults in the United States in 2015. Limited data suggest sugammadex is widely used in pediatric anesthesia practice however the factors influencing use are not known. We explore patient, surgical, and institutional factors associated with the decision to use sugammadex versus neostigmine or no reversal, and the decision to use 2 mg/kg vs 4 mg/kg dosing.
View Article and Find Full Text PDFRepetition of sugammadex up to an equimolar dose in cases of accidental subcutaneous rocuronium administration.
Eur J Anaesthesiol
January 2025
From the Department of Internal and Emergency Medicine, Kantonsspital Aarau, Aarau (YAW) and Department of Anaesthesia and Critical Care Medicine, Buergerspital Solothurn, Solothurn, Switzerland (FM).
Sugammadex: A savior for an elderly cardiac patient! A case report.
Saudi J Anaesth
October 2024
Department of Anaesthesiology, P.D. Hinduja National Hospital and Medical Research Centre, Mumbai, Maharashtra, India.
In an elderly patient with known cardiac and pulmonary risk, a reversal agent with a faster onset and least hemodynamic effects is preferable. Being inert, the sugammadex-rocuronium complex is associated with minimal muscarinic effects. We report a successful management with rocuronium and sugammadex in an eighty three year old male patient with a history of Ischemic Heart Disease, atrial fibrillation, and Interstitial Lung Disease posted for a cochlear implant surgery.
View Article and Find Full Text PDFAnalysis of characteristics of patients whose sugammadex claims were denied by the Auto Insurance Claims Review Department of Korean Health Insurance Review & Assessment Service: a retrospective single-center review.
Anesth Pain Med (Seoul)
November 2024
Department of Anesthesiology and Pain Medicine, Chosun University Hospital, Gwangju, Korea.
Background: Recently, there have been many cases where sugammadex used in traffic accident patients has been deducted from auto insurance claims. This study aims to investigate the characteristics of sugammadex deductions through retrospective analysis.
Methods: We included patients who underwent general anesthesia after traffic accidents at our institution between January 2019 and December 2023.
Efficient Reversal of Neuromuscular Blocking Agent-Induced Biological Functions and Side Effects by an Extended Biphen[3]arene Carboxylate.
J Med Chem
December 2024
State Key Laboratory of National Security Specially Needed Medicines, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, P. R. China.
Article Synopsis
- * A new compound called ExBP3C was developed as an effective reversal agent for multiple NMBAs, showing strong binding capabilities with agents like atracurium and rocuronium.
- * ExBP3C demonstrated better efficiency than the existing reversal drug sugammadex, and in tests, it rapidly corrected heart rate issues caused by an overdose of atracurium within two minutes, indicating good safety and biocompatibility.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!